(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 May 2022 (19.05.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/101469 A1

(51) International Patent Classification:
A61K 9/51 (2006.01) *A61K 39/00* (2006.01)
A61K 9/19 (2006.01) *A61P 31/14* (2006.01)

(21) International Application Number:
PCT/EP2021/081674

(22) International Filing Date:
15 November 2021 (15.11.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/114,478 16 November 2020 (16.11.2020) US
63/115,588 18 November 2020 (18.11.2020) US

(71) Applicant: **BIONTECH SE** [DE/DE]; An der Goldgrube 12, 55131 Mainz (DE).

(72) Inventors: **PANZNER, Steffen**; c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE). **REINSCH, Christian**; c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE). **THANKI, Kaushik**; c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE). **SOMANI, Sukrut**; c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE). **TCHESSALOV, Serguei A.**; c/o Pfizer Inc., 1 Burtt Road, Andover, Massachusetts 01810 (US). **BHATNAGAR, Bakul Subodh**; c/o Pfizer Inc., 1 Burtt Road, Andover, Massachusetts 01810 (US). **DARVARI, Ramin**; c/o Pfizer Inc., 1 Burtt Road, Andover, Massachusetts 01810 (US). **LUTHRA, Sumit**; c/o Pfizer Inc., 1 Burtt Road, Andover, Massachusetts 01810 (US).

(74) Agent: **SCHNAPPAUF, Georg**; Zwicker Schnappauf & Partner Patentanwälte PartG mbB, Hansastr. 32, 80686 Munich (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: COMPOSITIONS AND METHODS FOR STABILIZATION OF LIPID NANOPARTICLE MRNA VACCINES

(57) Abstract: The present disclosure provides technologies relating to stabilization of lipid nanoparticle mRNA compositions (*e.g.*, vaccines).

WO 2022/101469 A1